1. Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.

    Cancer Prevention Research 9(8):673 (2016) PMID 27261491 PMCID PMC4970896

    Methods to determine individualized breast cancer risk lack sufficient sensitivity to select women most likely to benefit from preventive strategies. Alterations in DNA methylation occur early in breast cancer. We hypothesized that cancer-specific methylation markers could enhance breast cancer ...
  2. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

    Journal of Clinical Oncology 34(14):1689 (2016) PMID 26884586

    To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor-positive breast cancer. ASCO convened an Update Panel and conducted a sys...
  3. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

    Oncologist 21(5):539 (2016) PMID 27009936 PMCID PMC4861358

    Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in patient-repo...
  4. Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.

    Cancer Research 76(7):2013 (2016) PMID 26787836 PMCID PMC4873448

    Efforts to induce the differentiation of cancer stem cells through treatment with all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silencing of the retinoic acid receptor (RAR)-β The histone deacetylase inhibitor entinostat is emerging as a promising a...
  5. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

    Clinical Cancer Research 22(6):1395 (2016) PMID 26463708 PMCID PMC4794377

    Aromatase inhibitors can exert unfavorable effects on lipid profiles; however, previous studies have reported inconsistent results. We describe the association of single-nucleotide polymorphisms (SNP) in candidate genes with lipid profiles in women treated with adjuvant aromatase inhibitors. We ...
  6. A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma.

    American Journal of Clinical Pathology 145(3):365 (2016) PMID 27124919

    Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. We searched clinical and pathology databases for patients with histologically confi...
  7. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

    Molecular & Cellular Proteomics 14(11):2887 (2015) PMID 26330541 PMCID PMC4638033

    Tamoxifen, an estrogen receptor-α (ER) antagonist, is an important agent for the treatment of breast cancer. However, this therapy is complicated by the fact that a substantial number of patients exhibit either de novo or acquired resistance. To characterize the signaling mechanisms underlying t...
  8. Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.

    Oncology (Williston Park, N.Y.) 29(11):828 (2015) PMID 26573062

    Research in the fields of surgical, medical, and radiation oncology has changed the landscape of neoadjuvant therapy in breast cancer, yet many areas of controversy still exist. When considering whether a patient is a candidate for neoadjuvant therapy, ideally the initial assessment should be mu...
  9. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    Breast Cancer Research and Treatment 154(2):263 (2015) PMID 26536870 PMCID PMC4807610

    Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimenta...
  10. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.

    Oncotarget 6(30):29143 (2015) PMID 26356563 PMCID PMC4745717

    Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers are triple negative breast cancer (TNBC) and are often highly aggressive when compared to other subtypes of breast cancers. To better characterize the biology that underlies the TNBC phenotype, we p...
  11. Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse.

    JAMA Oncology 1(5):569 (2015) PMID 26182336

  12. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.

    Clinical Cancer Research 21(14):3263 (2015) PMID 25813021 PMCID PMC4696069

    Glutamine addiction in c-MYC-overexpressing breast cancer is targeted by the aminotransferase inhibitor, aminooxyacetate (AOA). However, the mechanism of ensuing cell death remains unresolved. A correlation between glutamine dependence for growth and c-MYC expression was studied in breast cancer...
  13. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

    Journal of Clinical Oncology 33(17):1902 (2015) PMID 25847936 PMCID PMC4451173

    The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates. Patients with mTNBC re...
  14. Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk.

    Annals of Internal Medicine 162(10):JC11 (2015) PMID 25984872

  15. Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment.

    JNCI Monographs 2015(51):40 (2015) PMID 26063885 PMCID PMC4481707

    Breast cancer is the second leading cause of cancer death among US women, and the chance of a woman developing breast cancer sometime during her lifetime is one in eight. Early detection and diagnosis to allow appropriate locoregional and systemic treatment are key to improve the odds of survivi...
  16. Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection.

    Breast Cancer Research and Treatment 150(3):589 (2015) PMID 25788225 PMCID PMC4388316

    Preoperative sentinel node localization (SNL) using a subareolar injection of radiotracer technetium-99m-sulfur colloid (Tc(99m)SC) is associated with significant pain. Lidocaine use during SNL is not widely adopted partly due to a concern that it can obscure sentinel node identification and red...
  17. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

    Journal of Clinical Oncology 33(3):265 (2015) PMID 25512454 PMCID PMC4289722

    Treatment-emergent symptoms with adjuvant tamoxifen and aromatase inhibitors (AIs) have been associated with superior recurrence-free survival (RFS). We hypothesized that MA.27 anastrozole- or exemestane-treated patients with new or worsening vasomotor and/or joint symptoms would have improved R...
  18. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

    Journal of nuclear medicine : official publicat... 56(1):31 (2015) PMID 25476537 PMCID PMC4352313

    Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in wo...
  19. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

    Journal of the National Comprehensive Cancer Ne... 12(11):1629 (2014) PMID 25361808

    Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their ...
  20. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

    Cancer Immunology Research 2(10):949 (2014) PMID 25116755 PMCID PMC4211036

    Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide augments vaccine activity in tolerant neu mice and in patients with metastatic breast cancer. HER2-specific monoclonal antibodies...